MRNA

Moderna, Inc. (MRNA) - Q1 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2025. Moderna, Inc. is a biotechnology company developing mRNA medicines across respiratory virus vaccines, oncology therapeutics, and rare disease therapeutics. The company currently has two approved commercial products: Spikevax (COVID-19) and mRESVIA (RSV). The company operates as a large accelerated filer with 386.7 million shares of common stock outstanding as of April 25, 2025.

Key Financial Metrics

Margins: Cost of sales was $90 million, representing 104% of net product sales for Q1 2025, compared to 58% in Q1 2024. This increase is driven by lower sales volume against fixed manufacturing costs and inventory write-downs.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 35% year-over-year, driven primarily by a 49% drop in net product sales. COVID-19 sales fell from $167 million to $84 million due to reduced vaccination rates and seasonal demand. RSV sales contributed $2 million in Q1 2025.
• Expense Reductions: Operating expenses decreased 19% to $1,158 million. Research and development (R&D) expenses dropped 19% to $856 million due to lower clinical trial spend and program wind-downs. Selling, general, and administrative (SG&A) expenses fell 23% to $212 million.
• Inventory Charges: Cost of sales included $42 million in inventory write-downs (excess/obsolescence) and $10 million in losses on firm purchase commitments, largely related to COVID vaccine inventory and raw materials.
• Liquidity: Total cash and investments decreased by $1.1 billion from the prior quarter, primarily due to operating cash outflows and capital expenditures.

Guidance, Outlook, and Risks

• Outlook: Management anticipates a decline in full-year 2025 net product sales compared to 2024 due to lower expected vaccination rates and increased competition. RSV sales are not expected to be a significant portion of total sales in 2025. The company expects to fund operations for at least the next 12 months with current resources.
• Pipeline Updates:
  • COVID: Next-generation vaccine (mRNA-1283) has a PDUFA date of May 31, 2025.
  • RSV: Approval for high-risk adults (18-59) has a PDUFA date of June 12, 2025.
  • Flu: Seasonal flu vaccine (mRNA-1010) interim data expected summer 2025; Flu+COVID combination (mRNA-1083) approval targeted for 2026.
  • Deprioritization: Development paused for mRNA-1011/1012, mRNA-1020/1030, and preclinical PKU candidate (mRNA-3210).
• Legal Proceedings:
  • Pfizer/BioNTech: PTAB found two Moderna patents unpatentable in March 2025 (subject to appeal). A German court ruled in Moderna's favor regarding patent infringement, though damages are yet to be determined.
  • Arbutus/Genevant: Five international lawsuits filed in March 2025 alleging infringement of lipid nanoparticle patents.
  • GSK: Two U.S. lawsuits pending with trial dates set for 2027.
• Risks: Continued negative cash flows from operations, uncertainty in demand for seasonal vaccines, and potential impacts from ongoing patent litigation.

Investor Verification Checklist

• Inventory Valuation: Verify the magnitude of the $42 million inventory write-down and the remaining exposure to excess raw materials and finished goods.
• Patent Litigation Status: Monitor the appeal process regarding the PTAB decision on Pfizer/BioNTech patents and the outcome of the German damages ruling.
• RSV Commercialization: Assess the trajectory of mRESVIA sales following the Q1 2025 start of $2 million and the impact of new regulatory approvals in Australia, UK, Switzerland, and Taiwan.
• Cash Burn Rate: Confirm the sustainability of the $1.0 billion quarterly operating cash outflow against the $8.4 billion cash and investment balance.
• Next-Gen COVID Approval: Track the FDA decision on mRNA-1283 by the May 31, 2025 PDUFA date as a key revenue driver.